Prova Education: Changing the Practice of Medicine - Prova Education

Changing the Practice of Medicine

Changing the Practice of Medicine

Discover CME, tools, and guideline-focused education to
improve your knowledge - and patient outcomes.

Popular

EHA 2026: Sonrotoclax Plus Zanubrutinib in Frontline CLL
EHA 2026: Sonrotoclax Plus Zanubrutinib in Frontline CLL
Oncology and Hematology
EHA 2026: Sonrotoclax Plus Zanubrutinib in Frontline CLL
Chan Y. Cheah, MBBS
- Chan Y. Cheah, MBBS
EHA 2026: Long-Term Zanubrutinib Outcomes
EHA 2026: Long-Term Zanubrutinib Outcomes
Oncology and Hematology
EHA 2026: Long-Term Zanubrutinib Outcomes
Alessandra Tedeschi, MD
- Alessandra Tedeschi, MD
NEW EPISODE
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
MinuteCE®
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
0.50 program credits
NEW EPISODE
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
MinuteCE®
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
Erica L. Mayer, MD, MPH
0.50 program credits
- Erica L. Mayer, MD, MPH
0.50 program credits
MinuteCE®
Rapid Data Pulses From ASCO 2026: Emerging Data on Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO; Erica L. Mayer, MD, MPH
0.50 credits 3 episodes
- Aditya Bardia, MD, MPH, FASCO
- Erica L. Mayer, MD, MPH
0.50 credits 3 episodes
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Oncology and Hematology
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Sara A. Hurvitz, MD, FACP
- Sara A. Hurvitz, MD, FACP
Seeing the Invisible: Radiologic Precision to Enable Early Intervention in Bronchiectasis
Seeing the Invisible: Radiologic Precision to Enable Early Intervention in Bronchiectasis
CME/CE Broadcast Replay
Seeing the Invisible: Radiologic Precision to Enable Early Intervention in Bronchiectasis
Robert D. Suh, MD; Ashwin Basavaraj, MD
1.00 credit
- Robert D. Suh, MD
- Ashwin Basavaraj, MD
- Mary Salvatore, MD, MBA
1.00 credit
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
CME/CE Virtual Event
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
July 08, 2026
06:00 PM - 07:30 PM ET
1.50 credits

CME/CE

IBD Masterclass: Choosing the Right IBD Therapy - A Patient-Clinician Connection
IBD Masterclass: Choosing the Right IBD Therapy - A Patient-Clinician Connection
CME/CE
IBD Masterclass: Choosing the Right IBD Therapy - A Patient-Clinician Connection
Florence Odufalu, MD; Ugo Iroku, MD, MHS
0.50 credits
- Florence Odufalu, MD
- Ugo Iroku, MD, MHS
0.50 credits
A Q-Challenge™ Replay: Advancing Precision Diagnosis and Treatment Strategies in Acromegaly
A Q-Challenge™ Replay: Advancing Precision Diagnosis and Treatment Strategies in Acromegaly
CME/CE Broadcast Replay
A Q-Challenge™ Replay: Advancing Precision Diagnosis and Treatment Strategies in Acromegaly
Maria Fleseriu, MD, FACE; Shlomo Melmed, MBChB
1.00 credit
- Maria Fleseriu, MD, FACE
- Shlomo Melmed, MBChB
- Elise M. Brett, MD, FACE
1.00 credit
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
MinuteCE®
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
Adam J. Luginbuhl, MD
0.50 program credits
- Adam J. Luginbuhl, MD
0.50 program credits
MinuteCE®
Talking Through Treatment: Patient–Clinician Dialogue on Perioperative Immunotherapy in Locally Advanced HNSCC
Jennifer Johnson, MD, PhD; Adam J. Luginbuhl, MD
0.50 credits 5 episodes
- Jennifer Johnson, MD, PhD
- Adam J. Luginbuhl, MD
0.50 credits 5 episodes
All Hands on Deck: Multidisciplinary Coordination for Smarter Perioperative Care
All Hands on Deck: Multidisciplinary Coordination for Smarter Perioperative Care
MinuteCE®
All Hands on Deck: Multidisciplinary Coordination for Smarter Perioperative Care
Adam J. Luginbuhl, MD; Jennifer Johnson, MD, PhD
0.50 program credits
- Adam J. Luginbuhl, MD
- Jennifer Johnson, MD, PhD
0.50 program credits
Making the Right Moves in Metastatic CSPC: Intensification, Imaging, and Impact
Making the Right Moves in Metastatic CSPC: Intensification, Imaging, and Impact
CME/CE
Making the Right Moves in Metastatic CSPC: Intensification, Imaging, and Impact
Neeraj Agarwal, MD, FASCO; Rana McKay, MD
0.25 credits
- Neeraj Agarwal, MD, FASCO
- Rana McKay, MD
0.25 credits

Clinical Practice

Choosing the Path Forward: A Real-World Dialogue on Perioperative Immunotherapy
Choosing the Path Forward: A Real-World Dialogue on Perioperative Immunotherapy
MinuteCE®
Choosing the Path Forward: A Real-World Dialogue on Perioperative Immunotherapy
Adam J. Luginbuhl, MD
0.50 program credits
- Adam J. Luginbuhl, MD
0.50 program credits
Partnering Through Treatment: Preparing for Immunotherapy in the Perioperative Setting
Partnering Through Treatment: Preparing for Immunotherapy in the Perioperative Setting
MinuteCE®
Partnering Through Treatment: Preparing for Immunotherapy in the Perioperative Setting
Jennifer Johnson, MD, PhD
0.50 program credits
- Jennifer Johnson, MD, PhD
0.50 program credits
Turning Evidence Into Action: Applying Perioperative Data to Real-World Practice
Turning Evidence Into Action: Applying Perioperative Data to Real-World Practice
MinuteCE®
Turning Evidence Into Action: Applying Perioperative Data to Real-World Practice
Jennifer Johnson, MD, PhD
0.50 program credits
- Jennifer Johnson, MD, PhD
0.50 program credits
Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
CME/CE
Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
Enriqueta Felip, MD; Kristi Orbaugh, MSN, RNP, AOCN
0.25 credits
- Enriqueta Felip, MD
- Kristi Orbaugh, MSN, RNP, AOCN
0.25 credits
Putting It All Together: Challenges Addressed
Putting It All Together: Challenges Addressed
MinuteCE®
Putting It All Together: Challenges Addressed
David T. Rubin, MD; Ugo Iroku, MD, MHS
1.00 program credit
- David T. Rubin, MD
- Ugo Iroku, MD, MHS
1.00 program credit
Beyond Biology: Environmental and Lifestyle Influences in IBD
Beyond Biology: Environmental and Lifestyle Influences in IBD
MinuteCE®
Beyond Biology: Environmental and Lifestyle Influences in IBD
Sharon Dudley-Brown, PhD, FNP-BC, FAAN, FAANP; Florence Odufalu, MD
1.00 program credit
- Sharon Dudley-Brown, PhD, FNP-BC, FAAN, FAANP
- Florence Odufalu, MD
1.00 program credit

Programs

NEW EPISODE
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
MinuteCE®
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
Aditya Bardia, MD, MPH, FASCO
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
0.50 program credits
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Oncology and Hematology
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Sara A. Hurvitz, MD, FACP
- Sara A. Hurvitz, MD, FACP
Genetic Susceptibility in IBD: From Risk Genes to Clinical Impact
Genetic Susceptibility in IBD: From Risk Genes to Clinical Impact
MinuteCE®
Genetic Susceptibility in IBD: From Risk Genes to Clinical Impact
Michael Dolinger, MD, MBA
1.00 program credit
- Michael Dolinger, MD, MBA
1.00 program credit
MinuteCE®
IBD Masterclass: Foundations of Pathophysiology and Targeted Therapy
David T. Rubin, MD; Michael Dolinger, MD, MBA
1.00 credit 7 episodes
- David T. Rubin, MD
- Michael Dolinger, MD, MBA
- Florence Odufalu, MD
- Ugo Iroku, MD, MHS
- Sharon Dudley-Brown, PhD, FNP-BC, FAAN, FAANP
1.00 credit 7 episodes
Pathophysiology of IBD: The War Within
Pathophysiology of IBD: The War Within
MinuteCE®
Pathophysiology of IBD: The War Within
Florence Odufalu, MD
1.00 program credit
- Florence Odufalu, MD
1.00 program credit
Retina Rumble: Debating Modern Treatment Options
Retina Rumble: Debating Modern Treatment Options
CME/CE
Retina Rumble: Debating Modern Treatment Options
Roger A. Goldberg, MD, MBA; Christina Y. Weng, MD, MBA, FASRS
0.50 credits
- Roger A. Goldberg, MD, MBA
- Christina Y. Weng, MD, MBA, FASRS
- Yasha S. Modi, MD
0.50 credits